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Abstract
We previously reported that some systemic lupus erythematosus (SLE) patients have a population
of circulating memory B cells with >2-fold higher levels of CD19. We show here that the presence
of CD19hi B cells correlates with long-term adverse outcomes. These B cells do not appear anergic,
as they exhibit high basal levels of phosphorylated Syk and ERK1/2, signal transduce in response to
BCR crosslinking, and can become plasma cells (PCs) in vitro. Autoreactive anti-Smith (Sm) B cells
are enriched in this population and the degree of enrichment correlates with the log of the serum anti-
Sm titer, arguing that they undergo clonal expansion before PC differentiation. PC differentiation
may occur at sites of inflammation, as CD19hi B cells have elevated CXCR3 levels and chemotax
in response to its ligand CXCL9. Thus, CD19hi B cells are precursors to anti-self PCs, and identify
an SLE patient subset likely to experience poor clinical outcomes.
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INTRODUCTION
Systemic lupus erythematosus (SLE) is a severe, autoantibody-mediated disease affecting
multiple organ systems. The etiology is poorly understood, but has both genetic and
environmental components. Because anti-nuclear antibodies (ANA) are pathogenic in this
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disease[1;2], B cells are thought to play a pivotal role in the development and progression of
SLE. Apart from their role as producers of antibody, B cells may also mediate SLE development
and pathogenesis through their actions as antigen presenting cells (APCs) and producers of
cytokines[2;3;4;5;6;7;8;9]. Thus, understanding how B cell self-tolerance is broken in SLE is
important to the development of new therapeutic approaches.
With the exception of idiotypic markers such as 9G4 which is expressed predominantly by
autoreactive B cells, no clear phenotypic markers exist to identify precursors of autoantibody
producing cells, suggesting that autoreactive cells are generally indistinguishable from cells
recognizing foreign antigens. Human autoantibodies are predominantly IgG and somatically
mutated, suggesting that they are the product of germinal center responses. Both class-switched
(IgD−) and IgM (IgD+) memory B cells have been isolated from human tonsil, spleen, and
peripheral blood. These cells are typically CD38− and CD27+, although CD27− subsets have
also been described[10;11] and may frequently contribute a major fraction of the memory B
cell compartment in patients with active SLE[12]. CD19loCD38hi plasmablasts have also been
identified in human blood, and both of these populations are relatively expanded in SLE
patients[13;14]. Upon re-encounter with their cognate antigen, memory B cells proliferate,
after which some differentiate into plasma cells and others regenerate the long-lived memory
population.
B cell activation is dependent on multiple factors, including specificity and affinity for antigen
and the function of co-receptor molecules that act to amplify or dampen signals through the
BCR. Balance between these negative and positive modulators is important in establishing B
cell tolerance. CD19 is a BCR co-receptor that augments BCR signaling and has become of
significant interest in autoimmunity. It is a component of a multimeric protein complex that
includes CD21, CD81, and Leu-13[15] and can act as a signaling partner for multiple receptors,
including CD21, CD40, CD38, CD72, VLA-4, and FcγRIIB[16;17;18;19;20]. CD19 is
expressed by all B cells beginning at the pro-B stage, but is lost along with many other B cell-
specific proteins upon plasma cell differentiation[18]. Alterations in CD19 expression by B
cells affect their function and differentiation. In the absence of CD19, B cells are
hyporesponsive to BCR signaling and generate weak responses to T-dependent antigens, with
dramatically reduced germinal center formation; conversely, a high density of CD19 confers
hypersensitivity to BCR signaling and vigorous immune responses[21;22]. In mice, as little as
a 15% increase in CD19 expression induces a loss of B cell tolerance and autoantibody
production[16;23;24]. Thus, CD19 is critical to setting the threshold levels for the induction
of B cell tolerance and activation.
Crosslinking of CD19 with the BCR results in rapid phosphorylation of the cytoplasmic tail
of CD19 leading to a processive amplification of Lyn phosphorylation[25]. Activated Lyn
phosphorylates the immunoreceptor tyrosine-based activation motifs (ITAMs) on CD79a and
CD79b, the signaling subunits of the BCR, which provides a binding site for the Src family
tyrosine kinase Syk[25;26;27;28]. Perpetuation of this cascade leads to the activation of the
mitogen-activated protein kinases (MAPKs) extracellular signal-regulated kinase (ERK), c-
JUN NH2-terminal kinase (JNK), and p38 MAPK[27], which induce the transcription of genes
controlling proliferation, survival, and differentiation. In addition to its role in Lyn
phosphorylation, CD19 leads to the activation of Akt, which enhances B cell survival and
metabolic fitness. CD19 signals also synergize with BCR signals by a mechanism independent
of Ca++ and PKC to enhance the activation of the MAPK ERK1/2[29]. Thus, CD19 contributes
to B cell activation by inducing the activation of multiple pathways crucial to B cell function
in response to antigen stimulation.
Altered CD19 expression is evident in human autoimmunity. B cells from patients s with
systemic sclerosis have a 20% increase in CD19 expression[24], while SLE patient B cells
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have decreased CD19 expression compared to healthy control B cells[24;30;31]. In addition,
we, and others, have shown a population of B cells which have 2–3 fold increased levels of
CD19 compared to other B cells from the same patient or to healthy control B cells
(CD19hicells) in SLE, ANCA-SVV, and CVID patients[30;32;33]. We previously reported
that these CD19hi B cells have an activated memory phenotype, are class switched, and show
evidence of antigen selection[30]. We propose that the increased CD19 expression on
CD19hi memory B cells decreases their activation threshold leading to enhanced proliferation,
survival, and plasma cell differentiation. If the CD19hi memory B cell subset contains
autoreactive B cells, then a lower threshold of activation may lead to chronic activation and
production of autoantibody producing plasma cells.
Herein we show that the CD19hi population is enriched in autoreactive B cells, and that the
degree of enrichment correlates with autoantibody titer. Consistent with increased
autoreactivity, their presence correlates with poor clinical outcomes and possibly with poor
clinical response to B cell depletion by rituximab. Analysis of these cells suggests that they
are at a very early stage in plasma cell differentiation, are not anergic, and are likely to be
homing to sites of inflammation rather than the bone marrow. Thus, CD19hi B cells appear to
constitute a population unique to autoimmunity that contribute to autoantibody production and
that may play a pivotal role in disease pathogenesis.
MATERIALS AND METHODS
Healthy Control and Patient Clinical Samples and Data
Peripheral blood samples were collected from 10 healthy controls (mean age: 36.5 yrs, range:
27–54, gender: 8 female, 2 male) and 10 patients (mean age: 37 yrs, range: 23–53, gender: 10
female); in some cases, the same healthy control or patient was used in multiple occasions or
experiments. Five of the 10 patients from this study were patients continuing from the original
study[30], and the other five were newly identified. Patients were included in this study after
informed consent in accordance with our institutional internal review board, and fulfilled at
least four of the established American College of Rheumatology 1997 revised criteria for SLE.
Samples were gathered during routine clinic visits, and sera obtained from the same blood draw
as that for B cell analysis.
Table 1 is a prospective analysis of clinical outcomes of patients remaining in our study since
the previous publication[30] and details such as their medications can be found in that
manuscript. Clinical outcomes were determined by review of patient records.
Peripheral blood samples were collected into Vacutainer CPT tubes with sodium heprin (BD
Biosciences) and sera and peripheral blood mononuclear cells (PBMCs) isolated as per
manufacter’s protocol. PBMCs were washed once with sterile phosphate buffered saline (PBS)
before continuing with any protocol.
Flow Cytometry, Signaling Studies, and FACS
For surface staining, cells were prepared and stained as previously reported[30]. Signaling and
phosphoprotein studies were carried out using the BD Phosflow system as per manufacturer’s
Protocol 1 (BD Biosciences, San Diego, CA). Briefly, cells were resuspended at 2.5×106 cells/
mL in RPMI + 2% FBS and equilibrated at 37°C for at least 20 min. An equal volume of pre-
warmed, 2x solution of goat F(ab’)2 α-human IgG (10ug/mL final, Southern Biotech,
Birmingham, AL) or pansorbin (0.1% final, Calbiochem, La Jolla, CA) was then added with
vortexing, and cells were returned to 37°C for 10 min. Cells were then immediately fixed by
addition of pre-warmed Phosflow Fix Buffer 1, and Protocol 1 followed for permeabilization
and staining. Antibodies used were specific for, and labeled with: pSyk-PE, pERK-PE, Syk-
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FITC, pan ERK, pJNK, p-p38-FITC, Ki-67-FITC, CD19-APC, CD20-PE and-APC-Cy7, and
CD72-FITC (BD Biosciences, San Diego, CA); pAkt (Thr308) and pAkt (Ser473)-Alexa488
(Cell Signaling Technology, Boston, MA); CD180-PE (RP105), BR3-FITC, TLR4-PE, and
TLR9-PE (eBioscience, San Diego, CA). Unlabeled antibodies were labeled using Zenon
technology (Invitrogen, San Diego, CA). Appropriate pre-labeled or Zenon labeled isotype
controls were used in each experiment.
For propidium iodide (PI) staining, 5×105 cells were aliquoted, washed with cold PBS,
resuspended in 0.5mL cold PBS and permeabilized with 4.5mL cold 70% ethanol for 2 hrs at
−20°C. Cells were then pelleted, washed with cold PBS, and resuspended in 750uL of a solution
with 0.2 mg/mL RNase A, 0.02 mg/mL PI, 0.1% Triton X-100 (all from Sigma-Aldrich, St.
Louis, MO) and anti-CD20-FITC (recognizing the cytoplasmic domain, from BD Pharmingen,
San Diego, CA) in PBS and incubated for 1 hr on ice. Cells were then washed with PBS and
analyzed by flow cytometry.
For FACS, cells were prepared as described above and stained on ice for 20 min, then washed
twice. Antibodies used were specific for, and labeled with: CD19-APC, CD20-APC-Cy7, IgD-
FITC, and CD38-PE-Cy7 (BD Pharmingen, San Diego, CA). Cells were sorted using settings
to obtain maximum purity on one of two high-speed sorters (MoFlo, Dako Cytomation or
FACSAria, BD Biosciences). Post-sort analysis determined purity of populations at >90%.
RNA Extraction and Real Time PCR
Sorted cell populations were spun down, supernatant removed, and frozen at −80°C until RNA
extraction using RNeasy mini columns (Qiagen, San Deigo, CA) as per manufacturer’s
protocol. The reaction for generation of cDNA was carried out using a poly-A primer and
SuperScriptII Reverse Transcriptase (Invitrogen, San Diego, CA) according to manufacturer’s
protocol.
Real time PCR was carried out using TaqMan Gene Expression Assays, with β-Actin as an
endogenous control, as per manufacturer’s protocol (Applied Biosystems, Foster City, CA) on
an ABI Prism 7000 Sequence Detection System machine. Data were analyzed using ABI Prism
7000 software relative quantification study parameters. In each case, transcript expression,
normalized to β-actin expression, in sorted CD19hi cells is quantified relative to expression in
sorted CD19lo cells from the same patient or in sorted CD19+CD38−IgD− memory cells relative
to expression in all other CD19+ cells sorted from the same healthy control.
ELISpot
Anti-Sm and anti-IgG ELISpot protocols were adapted from those used in this lab for mouse
B cells[34]. Briefly, 96-well filter plates were coated with diluted Sm protein (Immunovision,
Springdale, AZ) or anti-human IgG (Bethyl Laboratories, Montgomery, TX). Sorted cells were
resuspended in DMEM supplemented with 10% FBS, 100U/mL Penicillin/Streptomycin
(Gibco Invitrogen, San Diego, CA), 0.1% β-mercaptoethanol (Gibco Invitrogen, San Diego,
CA), and 40ug/mL transferrin (BD Biosciences, San Diego, CA) and plated at 2.5×104 to
5×105 cells in 200uL/well with either media alone or with 15ug/mL anti-CD40, 100U/mL
rhIL-2, 100U/mL rhIL-10, (BD Pharmingen, San Diego, CA), and 0.01% pansorbin
(Calbiochem, La Jolla, CA). In each plate, CD19hi and CD19lo B cells, stimulated and non-
stimulated, were plated on both Sm and IgG coated wells and incubated for 6 days at 37°C
with 5% C02. They were then washed as previously described and incubated with an anti-
human IgG-HRP antibody (Bethyl Laboratories, Montgomery, TX) overnight at 4°C. The
plates were then developed and read as previously described[34]. Counts were normalized to
spots per million cells based on the number of cells plated in that well.
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The anti-Sm Elisa was carried out as previously described[30] using serum samples obtained
from the same draw as the cells sorted and plated in ELISpot. All four patient samples were
run on the same plate.
Statistical Methods
Comparisons for differences in outcomes by CD19 status were done using Fisher exact tests.
Fold-changes in all groups were first tested for significant differences from 1.0, representing
no difference, using two-sided rank tests. Comparisons between fold-changes between 2 groups
were evaluated using 2-sided Wilcoxon rank-sum tests. Comparisons between fold-changes
between 3 groups were first evaluated using Kruskal-Wallis tests, then if significant (p<0.05),
a ranked ANOVA was done to determine which groups were different at p-value of ≤0.05.
Significance between anti-Sm ASCs in the CD19hi vs. the CD19lo B cell groups was determined
by student’s t test.
RESULTS
The presence of CD19hi B cells correlates with adverse clinical outcomes
We previously reported that the presence of CD19hi B cells did not correlate with disease
activity in a cross-sectional study. However, there was a significant correlation with
immunological dysfunction and with severe neurological manifestations (seizures or
psychoses), which were seen in 2 of 14 CD19hi SLE patients and none of the 27 CD19lo SLE
patients[30]. We now report long-term clinical outcome data from this patient cohort over a
five-year period. As seen in Table 1, the presence of a CD19hi population was again
significantly associated with severe neurological involvement, as two additional CD19hi SLE
patients developed this complication, whereas none of the CD19lo SLE patients exhibited
neurological symptoms (p=0.01). In addition, there was a significant correlation with end stage
renal disease (ESRD, p=0.04), and overall presence of any one of four adverse outcomes
(severe neurological complications, ESRD, thrombic thrombocytopenic purpura (TTP), or
death due to disease complications, p=0.003). Although there was not sufficient statistical
power to determine significance in this study, there was also a >3-fold increase in disease-
related deaths in the CD19hi SLE patients. Taken together, these findings suggest that presence
of the CD19hi memory population identifies a subset of SLE patients with severe disease, and
suggests that these cells may play a role in the pathogenesis of neurological and renal
manifestations.
CD19hi patients in general have a poor clinical response to rituximab
Given the increased frequency of severe SLE among CD19hi patients, we evaluated the clinical
response to B cell depletion therapy with rituximab, a humanized anti-CD20 monoclonal
antibody. In SLE, the response to rituximab is variable; some patients experience long-term
clinical remission, while others experience short-term remission or no clinical response[13;
35;36]. In a survey of 17 SLE patients treated with rituximab, five possessed a CD19hi
population either before or after treatment with rituximab based on having a frequency of
CD19hi B cells that exceeded two-times the standard deviation above the mean percentage in
healthy controls[30]. Clinical response to rituximab was defined as an improvement in the
SLAM or SLEDAI score of at least 3 points. Clinical response duration was defined as the
time point where these disease activity indexes began to increase (relapse occurred), with the
SLAM and/or SLEDAI increasing by at least 3 points and/or an increase in the steroid dose
was required for disease control. As shown in Fig. 1, three of four CD19hi patients were short-
term responders to rituximab (9 months or less), and 1 did not respond. In contrast, almost half
(5 of 12) of CD19lo patients experienced a 12-month or longer remission, and of these, three
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had an extended, ongoing clinical response to rituximab treatment. Of the remaining seven,
three were short term and four were non-responders to treatment. Thus, although the sample
size is too small for statistical significance, these data suggest that an expanded CD19hi
population predicts a poor clinical response to rituximab treatment am ong SLE patients. The
possible poor clinical response to anti-CD20 depletion is not for lack of CD20 expression by
CD19hi B cells, as CD19hi B cells consistently expressed higher levels of CD20 than patient
CD19lo B cells or healthy control B cells (Fig. 1B).
The CD19hi population is enriched in autoreactive B cells
To determine whether CD19hi B cells contribute to autoantibody production, we tested whether
the CD19hi population is enriched in autoreactive B cells. Since the presence of a CD19hi
population is strongly associated with a high anti-Smith (Sm) serum titer[30], we measured
the frequency of anti-Sm IgG B cells in the CD19hi and non-CD19hi (CD19lo) populations by
ELISpot. We sorted CD19hi and CD19lo B cells from four SLE patients, three of whom
possessed a positive anti-Sm titer, and induced differentiation to PCs with pansorbin, anti-
CD40, IL-2, and IL-10 for 6 days on ELISpot membranes coated with purified Sm protein. No
anti-Sm antibody secreting cells were observed among the CD19hi or CD19lo B cells from the
patient that lacked an anti-Sm titer. However, significantly more anti-Sm IgG secreting cells
were present among CD19hi B cells than among CD19lo B cells (p=0.01, Fig. 2A) from the
remaining three patients. Importantly, the frequency of anti-Sm PCs within the CD19hi
population correlated exponentially with the serum anti-Sm titer (R2=0.99, Fig. 2B), suggesting
clonal expansion before differentiation to a PC.
CD19hi cells have a unique basal phosphorylation state
To determine whether increased CD19 alters BCR signaling, we measured basal and BCR
stimulated levels of phosphorylated signaling molecules. We compared the levels of
phosphorylated CD19, Syk, Akt, and the MAPKs ERK1/2, JNK, and p38 in CD19hi B cells
with those of CD19lo B cells from the same patient and healthy control B cells. The limited
numbers of CD19hi B cells that can be obtained precluded the use of standard Western blotting
methods; thus, we used flow cytometry to detect phosphorylated proteins in these cells. Flow
cytometry had the added benefit of also measuring the frequency of B cells within a population
that exhibited increased phosphorylation of a given protein.
To measure basal phosphorylation levels of these proteins, we stained for their presence
immediately following purification of peripheral blood monocytes (PBMCs). In each case a
healthy control blood sample was stained at the same time. There was a modest but significant
increase in the median fluorescence intensity (MFI) for phosphorylated CD19 (pCD19) in
CD19hi B cells compared to CD19lo B cells (average=1.5 fold, p=0.03). However, the increase
in the MFI for total CD19 protein (average=2.9 fold, p=0.03, Fig. 3A) was significantly higher
than the increase for pCD19 (p=0.02). Thus, a smaller proportion of CD19 was phosphorylated
in CD19hi B cells compared to CD19lo cells. Because CD19 phosphorylation amplifies Syk
activation[37], we were surprised to find that despite a lower frequency of CD19
phosphorylation, nearly all CD19hi B cells displayed significantly elevated levels of
phosphorylated Syk (pSyk) in contrast to the CD19lo B cells from the same patient and to
healthy control B cells (Fig. 3B–D). The MFI of pSyk in CD19hi cells was an average of 2.9-
fold greater than that for CD19lo B cells from the same patient or healthy control B cells.
Likewise, nearly all CD19hi B cells exhibited significantly elevated levels of pERK1/2 (average
2.9-fold) in contrast to CD19lo B cells from the same patient and to healthy control B cells
(Fig. 3B–D). Levels of total Syk and ERK protein were also elevated in CD19hi as compared
to CD19lo B cells (average 1.8- and 1.4-fold, respectively, Fig. 3C and D), but these increases
were significantly lower than increases in pSyk and pERK1/2 levels (Fig. 3D). It should be
noted that the pan-ERK antibody recognizes ERK family members in addition to ERK1/2, and
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therefore the increased ERK levels detected by this antibody may have overestimated the
increase in ERK1/2 expression. In contrast to Syk and ERK, we observed no significant
differences in basal phosphorylation levels of Akt or the MAP kinases p38 or JNK between
patient CD19hi B cells and patient CD19lo or healthy control B cells. In the case of Akt, no
increase in phosphorylation was detected at either phosphorylation site (Fig. 3D). Thus, ex
vivo CD19hi B cells exhibit an unusual phosphorylation phenotype, consistent with recent
antigen stimulation. Despite a lower frequency of phosphorylated CD19, nearly all cells
exhibited increased levels of pSyk and pERK1/2, but not increased phosphorylation of other
measured molecules downstream of the BCR and CD19.
CD19hi B cells are responsive to BCR stimulation
Since constitutively elevated pERK levels are associated with B cell tolerance[38], we sought
to determine whether crosslinking the BCR on CD19hi B cells results in signal transduction
and plasma cell differentiation. To determine whether BCR signaling is intact in CD19hi B
cells, healthy control and SLE B cells were stimulated with anti-IgG or pansorbin for 10
minutes and the levels of phosphorylated molecules determined by flow cytometry. Although
the kinetics of phosphorylation may vary for each molecule examined, due to limited cell
number we sought a time point at which phosphorylation of all measured molecules could be
observed in healthy control and SLE B cells. All five signaling intermediates and CD19 were
phosphorylated upon BCR stimulation in healthy control B cells and SLE CD19lo B cells (Fig.
4A–C), although a somewhat higher percentage of CD19lo B cells than healthy control B cells
phosphorylated these molecules (Fig. 4C). This was especially true for Syk (p=0.004) and
ERK1/2 (p=0.01), consistent with reports that SLE B cells are hyperresponsive to BCR
stimulation[30;39;40;41;42]. Importantly, BCR crosslinking increased the levels of
phosphorylated CD19, p38, JNK, and Akt in SLE CD19hi B cells similarly to healthy control
and CD19lo B cells (Fig. 4A and B). The frequency of CD19hi B cells that increased the levels
of each of these phosphorylated proteins was also similar to that of CD19lo and healthy control
B cells (Fig. 4C). In contrast, SLE CD19hi B cells exhibited little or no increase in the already
high basal levels of pSyk and pERK1/2 (Fig. 4A and B), or in the percentage of cells positive
for pSyk and pERK1/2 (Fig. 4C). Interestingly, the basal pSyk and pERK1/2 levels in
CD19hi B cells were similar to those reached by healthy controls and SLE CD19lo B cells after
BCR crosslinking, suggesting that ex vivo CD19hi B cells have already maximally
phosphorylated these molecules. Altogether, these data indicate that CD19hi B cells are not
refractory to BCR signaling.
To determine whether CD19hi B cells can be activated to become ASCs, we determined the
frequency of IgG antibody-secreting cells in CD19hi and CD19lo B cell populations by an
ELISpot assay with and without stimulation. As shown in Fig. 4D, an average of only 0.05%
(SEM 0.03%) of CD19hi cells spontaneously secreted IgG, ~7-fold less than CD19lo B cells
(0.34%, SEM 0.16%). However, stimulation with pansorbin, anti-CD40, IL-2, and IL-10, a
cocktail previously shown to induce robust IgG secretion in memory B cells[43], induced an
average of 14.6% (SEM 4.51%) of CD19hi B cells to secrete IgG, nearly twice that seen with
CD19lo B cells (7.9%, SEM 2.6%). This may be due to differences in the frequency of IgG+
B cells in each population or to an increased propensity of CD19hi B cells to become antibody-
secreting cells. Thus, the ability of CD19hi B cells to signal in response to BCR ligation and
their ability to differentiate to antibody-secreting cells upon stimulation suggest that CD19hi
B cells are not anergic.
CD19hi cells have a pre-plasma cell transcription profile
Our previous analysis suggested that CD19hi B cells are activated memory B cells. However,
the relationship between autoreactive B cell frequency and serum autoantibody titers suggests
a close relationship between these cells and the plasma cell pool in these patients. Thus, we
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sought to determine whether these cells were at an early stage in plasma cell differentiation by
measuring the levels of B cell- and plasma cell-specific transcription factors by RQ RT-PCR.
RNA from sorted CD19hi and CD19lo B cells from three patients was used to determine
expression levels of the B cell-specific transcription factors Pax-5 and Bcl-6 and the plasma
cell-specific transcription factors Blimp-1, IRF-4 and XBP-1. During differentiation to an
antibody secreting cell, Pax-5 and Bcl-6 are downregulated, and IRF-4, Blimp-1, and XBP-1
are upregulated[44]. As shown in Fig. 5A, CD19hi B cells showed significant downregulation
of Pax-5 and smaller but consistent downregulation of Bcl-6 compared to CD19lo B cells
(average RQ=0.34 and 0.49, respectively). However, they showed no significant upregulation
of Blimp-1, IRF-4, or XBP-1 expression (Fig 5A). Since >70% of CD19hi cells are
IgD−CD38− [30], we sorted IgD−CD38− memory B cells and all other CD19+ B cells from
three healthy controls and measured expression of these transcription factors to determine the
expression profile in healthy control memory B cells (Fig. 5B). No significant differences were
observed between the cells of these populations, including in Pax-5 expression (average
RQ=1.4). In addition, XPB-1 expression was decreased in healthy control memory B cells
compared to non-memory B cells, whereas it was not in CD19hi memory B cells compared to
CD19lo B cells. Thus, the low Pax-5 levels and relatively higher XPB-1 levels seen in
CD19hi B cells are not a general characteristic of memory B cells, suggesting that CD19hi cells
are at an early pre-plasma differentiative stage.
Since our findings indicate that CD19hi B cells may clonally expand before becoming plasma
cells, we determined whether they were actively undergoing cell division. As expected of
circulating B cells, CD19hi B cells were not actively undergoing cell division. As shown in
Fig. 5A and Table 2, CD19hi B cells did not express high levels of Ki-67, a protein present
only in proliferating cells, or exhibit an increase in DNA content, as measured by PI staining.
Thus, CD19hi B cells are not in S phase. However, they exhibited a small but consistent
(average 1.7 fold) increase in Ki-67 staining (Table 2), consistent with cells in G1 phase or just
entering or leaving S phase[45;46;47]. Thus, CD19hi B cells are not actively undergoing cell
division, indicating the clonal expansion that they undergo before becoming plasma cells
occurs after they exit the circulation.
CD19hi B cells have an unusual chemokine receptor expression profile
Long-lived plasma cells reside primarily in the bone marrow, and thus to determine whether
the CD19hi B cells are likely to be homing to the bone marrow, we compared the transcript
levels of CXCR4 and CXCR5 in CD19hi vs. CD19lo B cells. CXCR5 retains cells in the follicles
of secondary lymphoid tissues ([48]), and is normally downregulated during plasma cell
differentiation ([49]), while CXCR4 is responsible for directing plasma cell precursors to the
bone marrow and is normally upregulated during plasma cell differentiation ([50]). As shown
in Fig. 6A, CXCR4 transcripts were significantly lower in CD19hi B cells of all three patients
relative to CD19lo B cells (average RQ=0.1), as were CXCR5 transcripts in two of the three
patients (average RQ=0.36, overall average RQ=0.7). Similar to CD19hi B cells, healthy
control memory B cells had lower transcript levels of CXCR4 and CXCR5 compared to non-
memory B cells (average RQ=0.4 and 0.7, respectively, Fig. 6B), but these decreases were less
pronounced than in CD19hi B cells. While CXCR5 transcripts were similarly decreased in
CD19hi and healthy control memory B cells relative to their respective controls (Fig. 6A and
B), the relative decrease in CXCR4 transcripts by CD19hi B cells was ~4 times greater than
that in healthy control memory B cells (Fig. 6A and B). Thus, CD19hi B cells differ from
healthy control memory B cells in having a greater reduction in CXCR4 transcripts, casting
doubt on the ability of these cells to home to the bone marrow.
Since CD19hi B cells may not home to the bone marrow, we determined whether CD19hi B
cells could be homing to sites of inflammation. CXCR3 levels are elevated on a subset of
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memory B cells and plasma cells[50;51;52], in addition to T cells[53], and directs migration
to sites of inflammation where CXCR3 ligands are present at high concentrations[51]. As seen
in Fig. 7A, CXCR3 transcript levels were dramatically higher in CD19hi B cells compared to
CD19lo B cells of all three patients tested (average RQ=14.2, range= 7.6–24). This increase
was much higher than the ~2-fold increase in CXCR3 transcripts seen in healthy control
memory B cells compared to non-memory B cells (Fig. 6B). The increase in CXCR3 transcript
levels is reflected by a significant increase in CXCR3 protein on the cell surface of CD19hi B
cells (Fig. 6C). These results suggest that CD19hi B cells may home to sites of inflammation.
To confirm that increased expression of CXCR3 by CD19hi B cells is functionally significant,
we determined the ability of CD19hi B cells to migrate in response to CXCR3 and CXCR4
ligands. As shown in Fig 6D, CD19hi B cells migrated efficiently in response to the CXCR3
ligand CXCL9, but little or not at all in response to the CXCR4 ligand CXCL12 or to media
alone. These data affirm that CD19hi B cells are unlikely to migrate to the bone marrow and
indicate that the increased expression of CXCR3 on these cells is functionally relevant,
supporting the idea that CD19hi B cells are homing to sites of inflammation.
DISCUSSION
CD19hi B cells constitute a novel population of memory B cells that are present at a high
frequency in the peripheral blood of some SLE and ANCA-vasculitis patients[30]. Relevance
of the CD19hi B cell population to autoimmunity is indicated by the 3- to 10-fold enrichment
in anti-Sm B cells compared to the CD19lo population, and by the fact that the degree of
enrichment correlates with the level of serum anti-Sm antibody. In contrast, the frequency of
anti-Sm CD19lo B cells is not different between patients regardless of anti-Sm titer. Consistent
with an involvement in autoantibody production, CD19hi B cells do not appear to be anergic,
as BCR crosslinking induces phosphorylation of CD19, Akt, JNK and p38 to levels comparable
to those in CD19lo B cells from the same patient and to those in healthy control B cells. In
addition, BCR crosslinking, in conjunction with CD40 and cytokine signals, induces a high
frequency of CD19hi B cells to become PCs. Thus, the CD19hi B cell subset likely includes
the precursors to the majority of anti-Sm PCs in these patients. The finding that autoantibodies
specific for other small nuclear ribonucleoproteins correlate with the presence of this subset
in SLE patients[30] suggests that the CD19hi subset likely includes autoreactive B cells of other
specificities.
The frequency of anti-Sm B cells in the CD19hi population correlates linearly with the log of
the anti-Sm titer, such that a doubling of the frequency is associated with a ~100-fold increase
in titer. This suggests that CD19hi B cells undergo clonal expansion before becoming PCs, and
suggests further that the degree of clonal expansion varies as a function of CD19hi B cell
frequency. A possible explanation is that CD19hi B cells activate other inflammatory cells at
the site of plasma cell differentiation that enhance their proliferation, thereby creating a positive
feedback loop. Thus, the more CD19hi B cells present at the sites of differentiation, the greater
the proliferation and the greater number of plasma cells generated. The cells and cytokines
involved in driving CD19hi B cell clonal expansion remain to be identified, but T cell activation
would be consistent with the elevated surface expression of MHCII and CD86 in CD19hi B
cells[30], and with the ability of T cells to secrete cytokines known to induce B cell
proliferation.
CD19hi B cells have high basal levels of pSyk and pERK1/2, equivalent to those in CD19lo
and healthy control B cells after strong BCR crosslinking (Fig. 4B), suggesting that they have
recently received a BCR activating signal. The absence of elevated basal levels of pAkt in
CD19hi B cells seemingly contradicts the involvement of a BCR signal, since BCR signals
induce Akt phosphorylation[54]. The main pathway for both ERK1/2 and Akt phosphorylation
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is the recruitment of phosphatidylinositol 3-kinase (PI3K) to the BCR complex by CD19 and
its activation by Syk[27;55;56]. Thus, the high basal phosphorylation of Syk and ERK1/2
suggests that the Syk/PI3K/ERK pathway is activated in CD19hi B cells. One explanation for
the lack of Akt phosphorylation is that it may be more transient than ERK or Syk
phosphorylation[54], and therefore lost by the time the the cells can be analyzed. Alternatively,
Akt phosphorylation may be regulated downstream or independently of PI3K activation.
Indeed, Li and Carter[29] have demonstrated that CD19 signals synergize with BCR signals
to induce ERK1/2 activation at a point downstream of PI3K in B cells. Since Syk
phosphorylation is also downstream of CD19 phosphorylation, this could explain the high
levels of pSyk in these cells as well.
The low Pax-5 expression by CD19hi B cells suggests that CD19hi B cells are at an early stage
in plasma cell differentiation. This level of Pax-5 expression is not a characteristic of memory
B cells in general, since healthy control memory B cells express levels of Pax-5 that are not
different from non-memory B cells (Fig. 5B). Pax-5 is required for B cell differentiation and
activates the expression of genes that maintain B cell identity[44], including CD19. Thus, the
low levels of Pax-5 expression by CD19hi B cells suggest that these cells are differentiating
away from a B cell identity. In addition, although CD19hi and CD19lo B cells have similar
transcript levels of XBP-1, a transcriptional activator required for plasma cell differentiation,
healthy control memory B cells express considerably less XBP-1 transcript levels than control
B cells, suggesting that XBP-1 has increased in CD19hi B cells. Since Pax-5 represses the
expression of XBP-1[57], increased XBP-1 may follow from low Pax-5 levels. We did not
observe evidence of increased Blimp-1 transcript levels, and since transcription of PDRM1,
the gene for human Blimp-1, is repressed by Bcl-6[58], this is consistent with the normal
expression of Bcl-6 by CD19hi B cells. Blimp-1 is required for full plasma cell differentiation
and antibody secretion, but not for early plasmablast or pre-plasma cell formation[59]. Blimp-1
represses cell division[60], and thus low Blimp-1 levels is compatible with our hypothesis that
CD19hi B cells undergo clonal expansion before PC differentiation.
Chemokine receptor expression suggests a possible location for PC differentiation by
CD19hi B cells. Down-regulation of CXCR4 and non-responsiveness to its ligand CXCL12
suggests that CD19hi B cells are not migrating to the bone marrow, a common location for
long-lived PC differentiation[61]. Instead, our findings suggest that these cells are likely to be
transiting to sites of inflammation for PC differentiation, guided by high levels of CXCR3.
CXCR3 transcripts are ~14-fold higher in CD19hi B cells than in control CD19lo B cells, a
finding reflected in an increase in CXCR3 protein expression on the cell surface. This CXCR3
is functional, as CD19hi B cells chemotax in response to the CXCR3 ligand CXCL9. A subset
of human memory B cells and plasmablasts express CXCR3, and the expression of this
chemokine receptor is maintained after plasma cell differentiation[50;51;52]. The CXCR3
ligands CXCL9, CXCL10 and CXCL11 are highly expressed in peripheral sites of
inflammation, where, in autoimmunity and other highly inflammatory states, B cells can
differentiate to tissue-resident PCs[51;52;62;63;64]. For example, CXCR3 ligands are elevated
in the skin of patients with cutaneous lupus[65], the synovium of RA patients[64], and the
kidney and serum of SLE patients[66;67;68]. Interestingly, CXCR3 ligands are elevated in the
CNS of SLE patients with neurological involvement[69;70;71] and pre-PCs and PCs have been
found in the intrathecal tissue of SLE patients with CNS involvement[71]. Migration to the
kidney and CNS could account for the increased incidences of ESRD and severe neurological
dysfunction in CD19hi patients. Pathology may arise from locally high concentrations of
autoantibodies, and/or from the production of cytokines and activation of other inflammatory
cells[2;3;4;5;6;7;8;9].
The presence of CD19hi B cells in a subset of SLE patients may have implications for prognosis
and treatment. Although rituximab is a promising new therapy for SLE, not all patients have
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a robust clinical response[72]. This may be because not all B cell subsets are equally susceptible
to depletion. While PB B cells and follicular B cells are depleted efficiently, marginal zone
and memory B cells are less responsive to depletion, and plasma cells, which do not express
CD20, are not depleted at all[13;73]. We do not yet know how susceptible the CD19hi B cells
are to rituximab depletion, although they express high levels of CD20 compared to CD19lo B
cells from the same patient and from healthy control B cells. However, our data raise the
possibility that CD19hi patients are poor clinical responders to rituximab. This finding further
differentiates CD19hi patients as a distinct subgroup of SLE patients and suggests a predictive
test for clinical response to rituximab. Some of us have recently shown that SLE patients with
high titers of antibodies to Sm, snRNP, Ro, and La have decreased responsiveness to rituximab
[35]. This is consistent with the findings reported here, since the presence of CD19hi B cells
is associated with elevated titers of antibodies to Sm and other snRNP antigens[30].
In summary, the enrichment of autoreactive B cells within the CD19hi population and the
correlation of this enrichment with the serum autoantibody titer link this population to
autoimmunity. The presence of CD19hi B cells delineates a subgroup of SLE patients with
increased adverse clinical outcomes, and possibly a decreased response to rituximab treatment.
These findings not only point to this population as a possible therapeutic target, but also as a
marker for separating SLE patients into etiological and pathological subgroups that might
benefit from different treatment modalities.
Abbreviations
ANCA anti-neutrophil cytoplasmic antibody
SVV small vessel vasculitis
CVID common variable immunodeficiency
PB peripheral blood
Sm Smith
SLE systemic lupus erythematosis




ASC antibody secreting cells
TLR toll-like receptor
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Fig. 1. CD19hi patients are poor responders to rituximab treatment
A, Clinical response of CD19hi SLE patients and CD19lo SLE patients to rituximab treatment.
Response was defined as an improvement in the SLAM or SLEDAI score of at least 3 points
and duration of response defined as the time point at which these disease activity indexes
increased by 3 points or an increase in steroid dosage was required. NR=no response;
OG=ongoing response. B, Representative histograms showing gating for CD19hi and
CD19lo B cells from an SLE patient. Only CD19+ PB B cells are included in this gate. The
bottom histogram shows CD20 expression by CD19hi and CD19lo B cells and healthy control
B cells (all CD19+ B cells). Results are representative of 3 patients.
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Fig. 2. CD19hi B cells are enriched for autoreactivity, and the degree of autoreactivity in these cells
correlates exponentially with serum autoantibody titers
A, CD19hi and CD19lo B cells were sorted (using gates illustrated in Fig. 1B) from four patients
with differing anti-Sm titers, and ELISpot used to determine the number of anti-Sm IgG ASCs
in each group with and without stimulation by pansorbin, anti-CD40, IL-10 and IL-2. B, Anti-
Sm ASCs per million CD19hi or CD19lo B cells in each of four patients. Patient 1 did not have
detectable serum anti-Sm titer, and no anti-Sm ASCs were seen in either cell group. C, Anti-
Sm ASCs per million cells in each group vs. log10[anti-Sm serum titer], showing an exponential
relationship between the number of anti-Sm ASCs in the CD19hi B cell group and the serum
titer of anti-Sm in the corresponding patient.
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Fig. 3. Basal phosphorylative state of CD19hi cells
PB cells were permeabilized and stained using antibodies recognizing the indicated molecules.
Gating for CD19hi and CD19lo B cells is shown in Fig. 1B. A, Fold increase in MFIs of CD19
or phosphorylated CD19 (pCD19) in CD19hi vs CD19lo cells. B, Representative histograms
of PB cells from a CD19hi patient and healthy control (HC) stained for CD19 and pSyk,
pERK1/2, or an isotype control. Gating is on all CD19+ B cells. C, Representative single
parameter histograms showing staining for phosphorylated CD19 and phosphorylated or total
Syk and ERK1/2 in PB B cells from a healthy control (shaded) and CD19lo (thin line) and
CD19hi (thick line) B cells from the same patient. Gating is on CD19hi and CD19lo B cells as
shown in Fig. 1B. D, Fold increases in MFI for the labeled signaling molecules in CD19lo vs.
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CD19hi cells from the same patient. A and D, Each dot represents a different patient and/or
day. At least four different patients are included for each signaling molecule. * p≤0.05;
**p≤0.001.
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Fig. 4. CD19hi B cells respond to BCR crosslinking
A, Representative histograms of PB B cells from a CD19hi patient and a healthy control after
incubation with media alone or with anti-IgG for 10 min. Histograms are gated on CD19+ PB
B cells and the percentages give are of B cells falling within each indicated gate. B,
Representative single parameter histograms for each of the indicated phosphorylated molecules
in PB B cells from a healthy control and CD19lo and CD19hi B cells from a patient after
incubation with media (shaded) or pansorbin (line) for 10 min. Gating is illustrated in Fig. 1B.
C, Fold change in the percentage of cells falling into the positive gate for each of the
phosphorylated signaling molecules tested in cells incubated with media or pansorbin in a
healthy control or in CD19lo and CD19hi B cells from the same patient. Each point represents
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a different individual. D, CD19hi and CD19lo B cells (see Fig. 2A) were sorted and IgG antibody
secreting cells (ASCs) determined after incubation with either media alone or with pansorbin,
anti-CD40, IL-10 and IL-2 for 6 days. Each dot represents a different patient. * p≤0.05;
**p≤0.001.
Nicholas et al. Page 21













Fig. 5. CD19hi B cells have altered transcription factor expression
A and B, Transcription factor expression in indicated sorted B cell groups as determined by
RQ RT-PCR. Each bar represents a different individual. Gating for cell sorting is shown in
Fig. 1B. A, Relative expression in CD19hi B cells as compared to CD19lo B cells from the
same patient. B, Relative expression in CD19+CD38−IgD− memory B cells as compared to all
other CD19+ B cells from the same healthy control. C, Representative histograms for Ki-67
staining in non-lymphoid PBMCs (shaded) and CD19lo (thin line) or CD19hi (thick line) patient
PB B cells and for PI staining of indicated subsets. Percentages indicate cells falling into drawn
gate.
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Fig 6. CXCR expression in patient CD19hi and healthy control memory B cells
A and B, CXCR expression in indicated sorted B cell groups as determined by RQ RT-PCR.
Each bar represents a different individual. A, Relative expression in CD19hi B cells as
compared to CD19lo B cells from the same patient. B, Representative histogram of CD19+ B
cells from a healthy control showing gating of memory B cells (circled; CD38-, IgD-). The
non-memory B cells used were gated as all CD19+ B cells that fell outside this gate. Bars
represent relative transcript expression in CD19+CD38−IgD− memory B cells as compared to
all other CD19+ B cells from the same healthy control. C, Surface CXCR3 expression
determined by flow cytometry on healthy control B cells (shaded) or in CD19lo (thin line) or
CD19hi (thick line) B cells from the same patient. Histogram is representative of three patients.
D, Chemotaxis of CD19hi B cells in response to the CXCR3 ligand CXCL9, the CXCR4 ligand
CXCL12, or media alone. Migration was determined by collection, staining, and flow
cytometry of cells which migrated into lower wells after 90 minutes. No chemotaxis was
observed in response to CXCL12 and media alone by cells from patient 2.
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Table 1
Long-term Clinical Outcomes
Complication/Outcome CD19lo Patients CD19hi Patients p value
Severe Neurological 0% (0/27) 29% (4/14) 0.01
ESRD 4% (1/27) 29% (4/14) 0.04
TTP 7% (2/27) 7% (1/14) 1.0
Death 4% (1/27) 14% (2/14) 0.26
Any Adverse 15% (4/27) 64% (9/14) 0.003
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Table 2
Cell Cycle analysis of CD19hi B Cells
Fold Ki-671 CD19hi % PI High2 CD19lo % PI High
Patient 1 1.78 2.30% 2.80%
Patient 2 1.72 3.03% 3.51%
Patient 3 1.54 2.04% 2.04%
1
Fold increase in MFI for Ki-67 in CD19hi vs CD19lo B cells.
2
Percentage of CD19hi or CD19lo B cells falling into a gate indicating high propidium iodide content (S phase).
Clin Immunol. Author manuscript; available in PMC 2010 January 27.
